EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Seagen's Enterprise Value is $42,031 Mil.
Seagen's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was $-701 Mil. Therefore, Seagen's EV-to-FCF for today is -59.94.
The historical rank and industry rank for Seagen's EV-to-FCF or its related term are showing as below:
SGEN'
s EV-to-FCF Range Over the Past 10 Years
Min: -59.61 Med: -50.62 Max: -35.07
Current: -56.46
During the past 13 years, the highest EV-to-FCF of Seagen was -35.07. The lowest was -59.61. And the median was -50.62.
SGEN's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.9
vs SGEN: -56.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-27), Seagen's stock price is $228.74.
Seagen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.010. Therefore, Seagen's PE Ratio for today is At Loss.
Seagen EV-to-FCF Historical Data
The historical data trend for Seagen's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Seagen's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seagen's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seagen's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Seagen's EV-to-FCF falls into.
Seagen's current Enterprise Value is $42,031 Mil.
Seagen's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-701 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seagen (NAS:SGEN) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Seagen's share price for today is $228.74.
Seagen's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Seagen EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Seagen's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGEN has been successfully added to your 